- 1 Lasting changes to circulating leukocytes in people with mild SARS-CoV-2 infections
- 2 Allison E. Kennedy^{1,2,3}, Laura Cook^{4,5}, Jessica A. Breznik^{1,2,3}, Braeden Cowbrough^{1,2,3}, Jessica G. Wallace^{1,2,3},
- 3 Angela Huynh³, James W Smith³, Kiho Son^{3, 6}, Hannah Stacey^{1,2,7}, Jann Ang^{1,2,7}, Alison McGeer^{8,9}, Brenda L.
- 4 Coleman^{8,9}, Maggie Larché³, Mark Larché³, Nathan Hambly^{3,6}, Parameswaran Nair^{3,6}, Kjetil Ask^{3,6}, Matthew
- 5 S. Miller^{1,2,7}, Jonathan Bramson^{1,3}, Megan K. Levings^{10,11,12}, Ishac Nazy^{3,13}, Sarah Svenningsen^{3,6}, Manali
- 6 Mukherjee^{3,6}, Dawn M. E. Bowdish^{1,2,3,6*}
- 8 ¹McMaster Immunology Research Centre, McMaster University, Hamilton, Ontario, Canada
- ⁹ Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario,
- 10 Canada

7

25

- 11 ³Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton.
- 12 Ontario, Canada
- 13 ⁴Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia
- 14 ⁵The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Australia
- 15 ⁶Firestone Institute of Respiratory Health, St Joseph's Healthcare, Hamilton, Ontario, Canada
- ⁷Department of Biochemistry & Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada
- 17 ⁸Sinai Health, Toronto, Ontario, Canada
- 18 ⁹University of Toronto, Toronto, Ontario, Canada
- 19 ¹⁰School of Biomedical Engineering, University of British Columbia, Vancouver, British Columbia, Canada
- ¹¹Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada
- 21 ¹²British Columbia Children's Hospital Research Institute, Vancouver, British Columbia, Canada
- 22 ¹³McMaster Centre for Transfusion Research, Hamilton, Ontario, Canada
- 23 AEK and LC are Joint Senior Authors
- *Corresponding author. Email: bowdish@mcmaster.ca (DMEB)
- 26 **Short Title**: Immune changes after mild COVID-19

Abstract

Survivors of severe SARS-CoV-2 infections frequently suffer from a range of post-infection sequelae.

Whether survivors of mild or asymptomatic infections can expect any long-term health consequences is not yet known. Herein we investigated lasting changes to soluble inflammatory factors and cellular immune phenotype and function in individuals who had recovered from mild SARS-CoV-2 infections (n=22) compared to those that had recovered from other mild respiratory infections (n=11). Individuals who had mild SARS-CoV-2 infections had elevated levels of C-reactive protein 1-3 months after symptom onset, and changes in phenotype and function of circulating T cells that were not apparent in individuals 6-9 months post-symptom onset. Markers of monocyte activation and expression of adherence and chemokine receptors indicative of altered migratory capacity were also higher at 1-3 months post-infection in individuals who had mild SARS-CoV-2, but these were no longer elevated by 6-9 months post-infection.

Perhaps most surprisingly, polyclonal activation of T cells was higher in individuals who had recently experienced a mild SARS-CoV-2 infection compared to individuals with other recent respiratory infections.

These data are indicative of prolonged immune activation and systemic inflammation that persists for up to three months after mild or asymptomatic SARS-CoV-2 infections.

Introduction

SARS-CoV-2 infection has unusual effects on circulating immune cells. In general, respiratory infections are associated with rapid and sustained release of neutrophils and monocytes from the bone marrow, with no immediate change in production or function of lymphocytes [1]. In contrast, SARS-CoV-2 infections are consistently associated with lymphopenia, which is a reliable predictor of mortality [2]. The loss of T cells may be due to apoptosis in the secondary lymphoid organs, or possibly inappropriate recruitment to the lungs and other organs [3, 4]. Severe cases of SARS-CoV-2 infection are also associated with increased granularity and changes in nuclear morphology in neutrophils and monocytes, which are generally due to premature egress from the bone marrow and stunted maturation [5]. Whether myelopoiesis and egress are affected in mild COVID is not yet known.

Hospitalization with any respiratory infection is associated with long-term health consequences [6]; however, the consequences of COVID-19 appear to be particularly broad and include "long COVID" (a constellation of symptoms that can include severe fatigue often exacerbated by exercise; pain, and respiratory complications) [7, 8], and a higher than expected risk of re-hospitalization for a variety of causes [9-11]. Although it has been documented that there are differences in acute immune responses in asymptomatic, mild, moderate, and severe cases of SARS-CoV-2 infection [12, 13], it is not clear whether there is any risk of long-term immune dysregulation or health consequences in survivors of asymptomatic or mild cases.

We investigated whether there are any changes in phenotype and frequency of circulating leukocytes in individuals who had mild COVID-19 (i.e. did not require medical attention) and compared them to those who had other mild respiratory infections. We found evidence of transient changes in circulating NK cells, T cells, and monocytes 1-3 months post mild COVID-19 but not after other mild respiratory infections. These changes generally resolved 6-9 months post-COVID-19 infection, indicating

that there is an early period of immune dysregulation greater than that of other respiratory infections, which occurs even after mild SARS-CoV-2 infection.

Materials and Methods

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

Participant recruitment and blood collection

Research participants with symptoms consistent with COVID-19 (as summarized in Table 1) were recruited from the greater Hamilton area (Ontario, Canada) between February 2020 and January 2021. All protocols were approved by the Hamilton Research Ethics Board (#10757 and #11471). Venous blood was drawn in anti-coagulant free vacutainers for isolation of serum, and in heparin-coated vacutainers for experiments that required viable leukocytes. Serum and leukocytes were isolated as per standard protocols [14]. Immunophenotyping was performed on fresh blood within four hours of collection. None of the participants had been vaccinated against SARS-CoV-2 at the time of sample collection. Three donors who had a positive PCR test for SARS-CoV-2 were either asymptomatic or had mild symptoms (i.e. headache or tiredness that lasted for a day). The remaining donors had symptoms that they reported as consistent with a typical respiratory infection (e.g. cough, fever, chills) but these generally resolved within 2-4 weeks. The duration of symptoms and demographics of the 38 participants in this study (i.e. sex, age, body mass index, comorbid conditions, medications) are summarized in Table 1. Participants were characterized as having had COVID-19, 'other respiratory infection', or 'indeterminate', as detailed in S1 Table. Most participants did not consult a medical professional about their condition, consistent with the public health advice in the early months of the pandemic that individuals who did not need medical attention should stay home, and since none were hospitalized, we defined these as 'mild' infections. Donors recovered from COVID-19 gave blood either 1-3 months post-symptom onset or 6-9 months post-symptom onset, but no donor gave blood at both time points and therefore there were no repeat measures from the same donor.

Table 1. Participant demographics

Table 1. Participant demographics	Other receivates:			
	Other respiratory infections	COVID-19	Indeterminate n=5	P value *
	(not COVID-19)	infections		
	n=11	n=22	II=5	
Age (mean ± STDEV)	55 ± 16	55 ± 15	57 ± 11	0.9249
Sex (% female)	8 (73%)	11 (50%)	3 (60%)	0.3243
BMI (kg/m²)	24.0 ± 2.9	25.0 ± 3.6	24.5 ± 2.3	0.2783
Health Conditions (frequency)	24.0 ± 2.9	23.0 ± 3.0	24.3 ± 2.3	0.4172
Asthma	1 (9%)	1 (5%)	1 (20%)	-
COPD (including emphysema and chronic	1 (970)	1 (370)	1 (2070)	-
bronchitis)	1 (9%)	0 (0%)	0 (0%)	-
Other lung disease	0 (0%)	1 (5%)	0 (0%)	-
Diabetes	0 (0%)	3 (14%)	0 (0%)	-
Hypertension	1 (9%)	1 (5%)	1 (20%)	-
Heart disease	0 (0%)	2 (9%)	0 (0%)	-
Cancer	2 (18%)	2 (9%)	0 (0%)	-
Autoimmune condition	1 (9%)	1 (5%)	1 (20%)	-
Medications				1
Number of medications (mean ± STDEV)	1 ± 2	2 ± 2	1 ± 1	0.2049
Symptoms (frequency)				
Cough	6 (55%)	13 (59%)	2 (40%)	-
Shortness of breath	4 (36%)	9 (41%)	1 (20%)	-
Chest pain	3 (27%)	9 (41%)	2 (40%)	-
Fever	3 (27%)	12 (55%)	1 (20%)	-
Feeling generally unwell	9 (82%)	21 (95%)	2 (40%)	-
Abnormally tired	7 (64%)	20 (91%)	2 (40%)	-
New confusion	4 (36%)	1 (5%)	1 (20%)	-
New generalized muscle aches and pains	5 (45%)	16 (73%)	2 (40%)	-
New joint pain	3 (27%)	5 (23%)	2 (40%)	-
Earache/infection	0 (0%)	1 (5%)	0 (0%)	-
Headache	6 (55%)	14 (64%)	1 (20%)	-
Runny/stuffy nose	7 (64%)	7 (32%)	2 (40%)	-
Sinus pain	2 (18%)	4 (18%)	1 (20%)	-
Sore/scratchy throat	7 (64%)	10 (45%)	2 (40%)	-
Loss of appetite	4 (36%)	8 (36%)	2 (40%)	-
Loss of taste/smell	2 (18%)	11 (50%)	1 (20%)	-
Duration of Symptoms				
No symptoms - 1 week	4 (36%)	3 (14%)	1 (20%)	-
2-4 weeks	3 (27%)	11 (50%)	4 (80%)	=
4 or more weeks	4 (36%)	8 (36%)	0	-
Diagnosis				
PCR test for SARS-CoV-2 performed	0 (0%)	15 (68%)	0 (0%)	=
Told by a health care professional that they had SARS-CoV-2/COVID-19 without a PCR test	1 (8%)	5 (25%)	0 (0%)	-

*Statistical comparisons were made between 'other respiratory infections' and 'COVID-19 infections' groups only since the 'indeterminate' group was not used in subsequent analyses. Student's unpaired parametric t-test was used to compare age and BMI, which were normally distributed. Sex distribution was measured by Fisher's exact test to analyze a 2x2 contingency table. Differences in the number of medications, which was not normally distributed, was measured using an unpaired non-parametric test not assuming Gaussian distribution.

Measurements of anti-SARS-CoV-2 antibodies

Anti-SARS-CoV-2 full-length S protein and RBD IgG and IgA seropositivity were identified via validated serology ELISA as described by Huynh *et al.*, 2021 [15]. Briefly, NUNC™ Maxisorp 384 well plates (ThermoScientific) were coated with S (5 μg/mL) or RBD (2 μg/mL) antigens in 50 mM carbonate buffer (pH 9.6) overnight at 4°C and blocked with 3% skim milk in PBS-0.05% Tween-20. After washing with PBS, plates were coated with diluted serum (1:100) for 1 hour at room temperature, washed, and incubated with 25 μL alkaline phosphatase conjugated antibodies goat anti-human IgG (1:2000) or goat anti-human IgA (1:500) (Jackson Immuno). Plates were washed and antibody levels were quantified by adding 50 μL of substrate buffer (0.27 μM p-nitrophenyl phosphate/diethanolamine buffer, 1M, pH 9.6) and reading optical density (OD) at 405 nm detection every 1 min, with 490 nm reference.

Assessment of T cell activation induced markers (AIM) for SARS-CoV-2 peptides

To detect antigen-specific T cell recall responses, 100 μL of venous blood was cultured with an equal amount of Iscove's Modified Dulbecco's Medium Glutamax (Invitrogen Life Technologies) and antigen for 44 hours in 96-well flat bottom plates at 37°C. Wells were stimulated using SARS-CoV-2 peptide pools (PepTivators from Miltenyi Biotec) containing overlapping peptides covering the complete sequence of the membrane glycoprotein (M; #130-126-702), the nucleocapsid phosphoprotein (N; #130-126-699) or the immunodominant sequence domains of the spike glycoprotein (S; #130-126-701); each used 1 μg/mL. Unstimulated wells served as negative controls, and polyclonal stimulation with CytoStim[™] (0.5 μl/well, Miltenyi Biotec) was included as positive control. The fluorescently conjugated monoclonal antibody panel used for analysis is within S2 Table. Samples were run on a CytoFLEX LX (4 laser, Beckman Coulter). In this

AIM assay the antigen-specific T cells (AIM-positive) are defined by co-expression of CD25 and CD134 (OX40) for CD4⁺ T cells [16, 17] and by co-expression of CD69 and CD137 (4-1BB) for CD8⁺ T cells [18].

Quantification of peripheral immunophenotype

Circulating neutrophils, monocytes, T, B and NK cells were quantitated by multi-colour flow cytometry as previously described [14, 19]. Direct application of monoclonal antibodies (specificities outlined in S2 Table) to 100 µL of whole blood was performed for 30 minutes at room temperature. Following staining, samples were incubated with either 1 x Fix/Lyse Buffer (eBioscience) for 10 minutes or following standard protocols for the FOXP3 Transcription Factor Staining Kit (eBioscience), washed with PBS, and resuspended in FACS Wash (5 mM EDTA, 0.5% BSA in PBS) for analysis with a CytoFLEX LX (4 laser, Beckman Coulter). Absolute counts for circulating immune populations were determined using CountBright™ absolute counting beads (Invitrogen). Gating strategies and representative FACS dot plots to determine circulating immune populations are shown in S1 Fig.

Measurements of cytokines and C-reactive protein

Serum cytokines IL-6 and TNF and C-reactive protein (CRP) were measured using the Ella™

Automated Immunoassay System (Biotechne). Serum was diluted 1:2 as per the manufacturer's protocol.

The lower limits of quantification for CRP, IL-6, and TNF are 32 pg/mL, 0.28 pg/mL, 0.3 pg/mL, respectively.

Statistical analysis

Data and statistical analyses were done in FlowJo version 10.7.1, GraphPad Prism version 9, and R. Multiple group comparisons were tested using Welch's One-Way ANOVA and Games-Howell post-hoc test. As data were non-normally distributed, correlations were tested using Spearman correlation. Outliers were removed using Grubbs' test (α =0.05).

Results

other respiratory infections

Demographics and symptoms of individuals who had SARS-CoV-2 and

During the early phase of the COVID-19 pandemic (February – June 2020) diagnostic PCR testing in Ontario was generally limited to individuals who were hospitalized, had a confirmed exposure with an infected person, or had travelled to an area with active infections. At the time, public health advice was that people who did not need medical attention should self-isolate at home without being tested. Serologic studies have been used to estimate an infection rate of 0.5-1.5% during the March-June 'first wave' [20]. Compounding the lack of testing were the high rates of influenza and unusually high rates of respiratory syncytial virus (RSV) infections [21]. Consequently, some people with respiratory infections in this early period were told by a health care professional that they had COVID-19 without a nasopharyngeal swab PCR test, and not all of our study participants with symptoms of mild respiratory illness had COVID-19 (Table 1). Participants were classified as having had COVID-19 if they received a positive diagnostic PCR test and/or had anti-SARS-CoV-2 antibodies (S1 Table). There were no statistically significant differences in age, sex, BMI, co-morbidities, medications, or duration of symptoms between individuals that had mild COVID-19 (n=22) and individuals that had other mild respiratory infections (n = 11, Table 1).

Survivors of mild SARS-CoV-2 infections have reduced T cell responses to SARS-CoV-2 peptides 6-9 months post symptom onset

Lymphopenia is commonly reported in severe SARS-CoV-2 infections; however, it is not clear whether mild infections impact T cell numbers or function. We measured T cell responses to the SARS-CoV-2 structural membrane protein (M), nucleocapsid protein (N), and immunodominant regions of the spike (S) protein in all participants. After 44 hours incubation with antigen this assay identifies antigen-specific

CD4⁺ T cells by induced co-expression of CD25 and CD134 (OX40) and antigen-specific CD8⁺ T cells by co-expression of CD69 and CD137 (4-1BB) (Fig 1A) [22, 23]. A positive assay result was defined as > 3 standard deviations above an unstimulated sample (negative control well) and consisting of at least 20 events. We identified 5 individuals who had mild respiratory symptoms, did not have a positive diagnostic PCR test, and were seronegative for SARS-CoV-2 antibodies but had detectable levels of SARS-CoV-2 reactive T cells to some, but not all, of the SARS-CoV-2 M, N, and S peptides (S1 Table). Although it is possible these individuals had been infected with SARS-CoV-2 and had antibodies at some point, these data are also consistent with reports of pre-existing cross-reactive T cells to SARS-CoV-2 antigens in as many as 30% of individuals [24]. Consequently, we classified these 5 individuals as "indeterminate" and did not include them in subsequent analyses (their demographic data is summarized in Table 1).

Fig 1. CD4⁺ and CD8⁺ T cell responses to the M, N, and S peptide pools after mild SARS-CoV-2 infection. A) The number of SARS-CoV-2 specific T cells is measured as a percent of CD4⁺ T cells expressing both CD25 and OX40 or CD8⁺ T cells expressing both CD69 and CD137 after activation with the S, M or N peptide pools 1-3 months and 6-9 months after infection. The polyclonal activator Cytostim is used as a positive control.

B) All COVID-19 seropositive donors had an increase in CD25⁺OX40⁺CD4⁺ T cells in response to at least one of the M, N or S antigens 1-3 months after mild COVID-19 infection compared to seronegative individuals recovered from other mild respiratory infections. Each participant is indicated by a single data point: other respiratory infection n=11; 1-3 months post COVID-19 infection n=11; 6-9 months post COVID-19 infection n=8. Multiple group comparisons were tested using Welch's One-Way ANOVA and Games-Howell post-hoc test; bars represent the mean ± standard deviation. *P<0.05; **P<0.01; ***P<0.001

For analysis of the T cell responses, we split our cohort into those without antibody or T cell responses to SARS-CoV-2 (other respiratory infection; n=11) and those with antibody responses to SARS-

CoV-2 (COVID-19; n=22), the majority of whom also had detectable T cell responses to SARS-CoV-2 M, N, and S antigens (90.9%; n=20/22) (Fig 1; S1 Fig). Of the 22 participants who had COVID-19 infections, 14 provided samples 1-3 months post-symptom onset and 8 provided samples 6-9 months post-symptom onset. Consistent with other reports of lasting memory T cell responses to SARS-CoV-2 infection [13], we observed that all COVID-19 participants that provided samples at 1-3 months or 6-9 months post-symptom onset had generated T cell memory to at least one of the M, N and S peptides pools (Fig 1B, S3 Table). These data are consistent with previous observations that survivors of mild infections have lasting memory responses [13], however, there appear to be long-term differences in T cell functionality in COVID-19 survivors.

We saw similar frequencies of CD4⁺ T cell responses to all SARS-CoV-2 antigens and these were highest in COVID-19 patients 1-3 months post symptom onset (means of ~3-4% of CD4⁺ T cells), being significantly higher than in individuals with other respiratory infections (Fig 1B). Compared to COVID-19 patients 1-3 months post symptom onset, responses were reduced in COVID-19 patients 6-9 months post symptom onset and were not significantly different to those in individuals recovered from other respiratory infections. Similar results were found for CD8⁺ T cell responses, being highest in COVID-19 patients 1-3 months post symptom onset (means of ~0.4-0.5% of CD8⁺ T cells) although there were no significant differences between groups.

Survivors of mild SARS-CoV-2 infections have evidence of sustained inflammation 1-3 months post symptom onset

Prolonged immune activation can occur after recovery from severe infections and is thought to contribute to malaise and other symptoms in survivors [25]. One of the unusual features of COVID-19 is that a significant number of patients with mild to moderate illness report symptoms weeks to months after infection, despite having cleared the virus [26]. Although the participants in our study generally had

symptoms resolve within 1 month post infection (Table 1), we have nonetheless found evidence of prolonged inflammation. Seropositive individuals had higher levels of CRP, TNF, and IL-6 in circulation 1-3 months post-symptom onset; but in samples from individuals 6-9 months post-symptom onset, levels were equivalent to those individuals who were seronegative and were recovered from other respiratory infections (Fig 2A, B & C).

Figure 2. Transient increases in soluble mediators of inflammation occur after mild SARS-CoV-2 infection.

A) CRP levels in serum were higher 1-3 months after mild COVID-19 infection, and there was a trend towards remaining elevated 6-9 months after mild COVID-19 infection, compared to levels observed in seronegative individuals after other respiratory infections. Serum TNF levels (B) and IL-6 levels (C) were higher 1-3 months after COVID-19 infection but returned to levels seen in individuals who had other respiratory infections by 6-9 months. Each participant is indicated by a single data point: other respiratory infection n=11; 1-3 months post-COVID n=9-12; 6-9 months post-COVID n=8. Multiple group comparisons were tested using Welch's One-Way ANOVA and Games-Howell post-hoc test; bars are presented as mean ± standard deviation. *P<0.05; **P<0.01.

Surprisingly, there were differences in the degree of epitope independent polyclonal activation of T cells between the COVID-19 and non-COVID-19 groups. When whole blood was stimulated with Cytostim, which acts like a superantigen by crosslinking TCR (regardless of Vβ usage) and MHC, there was a statistically significant difference in the percent of CD25⁺OX40⁺CD4⁺ T cells and CD69⁺CD137⁺CD8⁺ T cells in COVID-19 patients 1-3 months post-symptom onset (Fig 3A&B). Whether this superantigen-like crosslinking activation contributes to, or is a result of, systemic inflammation is not clear, but CRP levels correlate with the percent of Cytostim-activated CD4⁺ T cells (Fig 3C). The Cytostim-activated T cells in the COVID-19 group also had higher expression levels of OX40, CCR6, CCR4 and CD69 than the other respiratory infection

group, implying a stronger activation (Fig 3D). Although these levels of OX40 and CD69 were reduced in samples collected 6-9 months post-symptom onset compared to samples collected 1-3 months post-symptom onset, levels of CCR4 and CCR6 remained similar. Collectively these data imply that there may be subtle changes in inducible T cell activation in convalescent SARS-CoV-2 patients that do not occur in response to other respiratory infections.

Figure 3. Evidence of prolonged T cell activation after mild SARS-CoV-2 infection.

The polyclonal activator Cytostim was used to measure T cell responses. COVID-19 seropositive individuals had a higher proportion of CD4⁺ (A) and CD8⁺ (B) activated T cells 1 to 3 months after infection compared to seronegative individuals after other respiratory infections. C) The number of CD4⁺T cells that responded to polyclonal stimulation correlated with CRP in COVID-19 seropositive individuals. D) Activation markers on the Cytostim-responsive CD4⁺T cells OX40, CCR6, CCR4, and CD69 were higher 1-3 months after COVID-19 infection compared to after other respiratory infections. Each participant is indicated by a single data point: other respiratory infection n=7-11; 1-3 months post COVID-19 infection n=11-12; 6-9 months post COVID-19 infection n=5-8. Multiple group comparisons in A-B and D were tested using Welch's One-Way ANOVA and Games-Howell post-hoc test; bars are presented as mean ± standard deviation. Data in C was assessed by Spearman's rank correlation. *P<0.05; **P<0.01.

Survivors of mild SARS-CoV-2 infections have changes in circulating immunophenotype 1-3 months post-symptom onset

The total numbers of circulating CD45⁺ cells, CD4⁺ T cells and CD8⁺ T cells were not different between individuals who had other respiratory infections and those who had COVID-19 at either 1-3 months or 6-9 months post symptom onset (Fig 4A-C). Compared to participants who were recovered from

other respiratory infections, there was an expansion of T_{regs} (CD45*CD3*CD4*CD25*CD127^{low}FOXP3*) and a decrease in NK cells (CD45*CD56*/NKp46*) in COVID-19 patients at 1-3 months post-symptom onset that returned by 6-9 months post-symptom onset to levels observed in individuals with non-COVID-19 respiratory infections (Fig 4D,G). We also measured the proportions of circulating naïve (CD45RA*CCR7*), central memory (CD45RA*CCR7*), effector memory (CD45RA*CCR7*), terminally differentiated effector memory cells re-expressing CD45RA (T_{EMRA}; CD45RA*CCR7*), and terminally differentiated (CD45RA*CCR7* CD57*CD28*) CD4* and CD8*T cells. Compared to patients with non-COVID-19 respiratory infections, there was an expansion of central memory CD4* cells and terminally differentiated CD8*T cells in COVID-19 patients at 1-3 months post-symptom onset that returned to levels observed in patients with other respiratory infections by 6-9 months post-symptom onset (Fig 4E,F). There were no significant differences between participants who had other respiratory infections and those who had COVID-19 for any other measured CD4* and CD8*T cell subsets.

Figure 4. Transient changes in circulating lymphocytes occur 1-3 months after COVID-19 infection.

Absolute numbers of circulating CD45⁺ cells (A), CD4⁺ T cells (B), and CD8⁺ T cells (C) were not different after 1-3 months or 6-9 months post-symptom presentation in seropositive individuals recovered from mild COVID-19 infection compared to seronegative individuals recovered from other respiratory infections; however, NK cell numbers (D) were lower in the 1-3 months post-COVID-19 infection group. At 1-3 months post recovery from COVID-19 there was an increase in CD45RA*CCR7* central memory CD4* cells (E) and an increase in CD45RA*CCR7*CD57*CD28* terminally differentiated CD8* T cells (F) compared to individuals recovered from other respiratory infections, but these differences were not apparent in individuals who had recovered from COVID-19 6-9 months prior. (G) Levels of circulating regulatory T cells (measured as a % of CD4* T cells) were higher in individuals 1-3 months post COVID-19 infection. Each participant is indicated by a single data point: other respiratory infection n=11; 1-3 months post COVID-19 infection

n=11-13; 6-9 months post COVID-19 infection n=8. Multiple group comparisons were tested using Welch's One-Way ANOVA and Games-Howell post-hoc test; bars are presented as mean ± standard deviation.

*P<0.05.

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

Six months after SARS-CoV-2 infection there was a statistical trend towards a lower ratio of myeloid to lymphoid cells, though this was due to a non-significant decrease in neutrophil numbers rather than changes in numbers of monocytes (Fig 5A-C). However, as circulating monocytes are a sensitive marker of chronic inflammation, we assessed monocyte subsets as well as their expression of migratory and activation markers (Fig 5D, S4 and S5 Tables). Classical monocytes (CD14⁺CD16⁻) expressing CCR2 are the first to leave the bone marrow. They have a half-life in the circulation of less than 24 hours since they are either recruited to sites of acute inflammation in response to CCL2/MCP or differentiate into CX₃CR₁expressing intermediate (CD14⁺CD16⁺) monocytes [27, 28]. Classical monocytes increase in the circulation during acute infection so, as expected, there was no difference in the number of circulating monocytes after COVID-19 infection had resolved (Fig 5C). Surprisingly, at 1-3 months after infection levels of CCR2 were lower on intermediate and non-classical monocyte populations (Fig 5D), implying that cells with the highest levels of CCR2 emigrated from the circulation. In general, the chemokine receptor CX₃CR₁ is expressed more highly on intermediate and non-classical (CD14^{low}CD16⁺) monocytes and is associated with recruitment to the tissues or vasculature and repair of damage in response to CX₃CL₁/fractalkine [29, 30]. A transient decrease in CX₃CR₁-expressing classical monocytes was found 1-3 months post COVID-19 infection, which likely indicates that monocytes with the highest levels of CX₃CR₁ (and therefore the most responsive to CX₃CL₁) had emigrated from the circulation. Expression of the integrin CD11b was also transiently increased on monocytes at 1-3 months post-symptom onset, but not neutrophils (data not shown), providing further evidence of transient but systemic immune activation and possible changes in the migratory capacity of monocytes after mild SARS-CoV-2 infection.

Figure 5. Evidence of sustained cellular inflammation after mild SARS-CoV-2 infection.

A) There was a trend towards a decreasing ratio of myeloid to lymphoid cells after SARS-CoV-2 infection, compared to individuals recovered from other infections, which was driven by a decrease in circulating neutrophils (B). Although total monocyte numbers did not change after infection (C), surface expression of the migratory markers CX₃CR₁ and CCR2 decreased transiently (D). Concurrent increases in surface expression of the migration and activation marker CD11b implies that the monocytes were activated. E) Correlation analysis (Spearman's correlation) of SARS-CoV-2 specific CD4* and CD8* T cell responses with measures of monocyte activation and migratory potential. Multiple group comparisons in A-D were tested using Welch's One-Way ANOVA and Games-Howell post-hoc test; in A-C bars are presented as mean ± standard deviation and each dot indicates a participant. The spread of expression of monocyte surface markers in D was visualized by concatenating uncompensated CD45*CD19*CD3*CD56*CD11b*HLADR*CD14* events in Flowlo for each infection group prior to overlaying geometric mean fluorescence intensity expression data from all donors onto the same histogram plot. Other respiratory infection (grey) n=11, 1-3 months after COVID-19 infection (red) n=14, 6-9 months from COVID-19 infection (pink) n=8. Data in E were assessed with the rcorr function in the Hmisc package in R and only statistically significant associations are shown. *P<0.05.

Changes in monocyte activation markers could be due to the increase in basal inflammation or could be proportionate to the SARS-CoV-2 specific immune response. We found that decreasing CX₃CR₁ expression was most strongly associated with the percentage of S-antigen specific CD4⁺T cells (p=0.0389) and that there was a strong association between M-antigen specific CD8⁺T cells and HLA-DR expression on non-classical/patrolling monocytes (p=0.0198) (Fig 5E). Importantly, there was no relationship between polyclonal T cell activation (i.e. Cytostim) and myeloid activation, implying that these changes are not due

to the general increase in T cell activation observed in convalescent patients, but rather SARS-CoV-2 specific responses.

Discussion

Infections severe enough to require hospitalization can have long-term health consequences, but one of the unusual features of COVID-19 is that a significant proportion of mild infections have lasting cardiovascular, respiratory, and neurologic consequences [26, 31]. The range of long-term health consequences and the multi-organ immune pathology observed post-SARS-CoV-2 infection implies that there may be a greater degree of immune dysregulation than that commonly observed after infection with other respiratory pathogens. Importantly, the participants in this study did not have "long-COVID" in that they reported that their symptoms were mild and had mostly resolved within 2-4 weeks (Table 1); however, participants with even mild COVID-19 symptoms experience elevated inflammation and immune activation that endures at least 1-3 month after their infection had resolved. The fact that these participants had increased measures of systemic inflammation (e.g. CRP), and lasting phenotypic and functional changes to both monocytes and T cells, implies that inflammatory responses to mild COVID-19 infections are more protracted than expected.

The proportions of memory CD4⁺ and CD8⁺ T cells specific for SARS-CoV-2 S, M, and N proteins we observed were consistent with those reported for convalescent patients who had had more severe infections, implying that disease severity is not proportionate to SARS-CoV-2 memory T cell responses [24, 32]. Previous studies have reported differences in the expression of activation markers on SARS-CoV-2 specific memory CD4⁺ T cells between exposed but seronegative individuals compared to those who had either mild or severe infections [13]; however, to our knowledge, this is the first report of elevated activation of *non*-SARS-CoV-2 specific T cells (i.e. Cytostim treated) in convalescent COVID-19 patients.

Cytostim-activated CD4⁺ T cells in participants with mild COVID-19 1-3 months post-symptom onset, compared to those in participants recovered from other respiratory infections, had higher expression of the activation markers OX40, CCR4, CD69 and CCR6, and OX40 and CD69 expression remained elevated after 6-9 months post-symptom onset. There were no differences between participant groups in the expression of activation markers on circulating unstimulated cells (data not shown), demonstrating that these differences are restricted to polyclonally activated cells. There are several possible explanations for this result. CD4⁺ T cells from 1-3 months post-symptom onset of COVID-19 may be primed to respond quicker and stronger to activation signals. Alternatively, since the number of activated CD4⁺ T cells in this participant group correlated strongly with rising CRP levels, it is also possible that there may be circulating cytokines (e.g. IL-6) or other factors that lower the threshold for T cell activation.

Our observations of transient increases in central memory CD4 $^{+}$ T cells and terminally differentiated CD8 $^{+}$ T cells are consistent with T cell responses to acute infection 35 ; however, a pronounced increase in regulatory T cells is generally associated with minimizing pathology during the acute, not the convalescent, phase of respiratory viral infections [33, 34]. Severe SARS-CoV-2 infections are associated with the development of autoantibodies that contribute to severity [35]. Mild SARS-CoV-2 infections are associated with autoimmune inflammatory syndromes (e.g. arthritis, vasculitis) after the primary infection has resolved [36, 37]. Whether this expansion of T_{regs} protects from autoimmune sequelae is not clear but this has been reported to occur after other zoonotic infections [38]. Appropriate regulation of T_{regs} may be especially important in SARS-CoV-2 infections, since pathology of these infections are caused in part by dysregulation of TGF- β production, a major cytokine produced by T_{regs} [39] that is required for their appropriate differentiation[40].

Severe COVID-19 infections are associated with a dysregulation of myelopoiesis that is so extreme that monocytes and neutrophils are unrecognizable by blood smear [41] and have dramatic changes in granularity, size and surface marker expression [42]. Both mild and severe COVID-19 are associated with

changes in number and migratory potential of dendritic cells for at least 7 months post infection [43]. We do not know if the transient changes in expression of CCR2 and CX₃CR₁ on circulating monocytes 1-3 months after infection are due to emigration of cells with the highest expression of those markers to inflamed or damaged tissues, however, CCL2 has been implicated in recruitment of monocyte to the lungs during infection [44]. The observation that decreasing CX3CR1 is associated with the level of SARS-CoV-2 specific T cells may imply that there is a relationship between immune responsiveness and innate immune activation. These observations in combination with the elevated expression of monocyte CD11b, which increases during acute and chronic inflammation and alters monocyte migration and adherence to the vasculature [45], imply even though the symptoms of mild COVID-19 infection may resolve in weeks, immune activation persists for at least 1-3 months.

Collectively, these data provide evidence that mild, and in some individuals even asymptomatic SARS-CoV-2 infections, can lead to sustained immune activation after resolution of symptoms, which is not observed in response to other mild respiratory infections. Whether this immune activation is more pronounced in patients with long-COVID, or more serious infections, remains to be seen.

Acknowledgements

The authors would like to thank Dr. Brian Dixon, Dr. Marc Aucoin, Dr. Mark Bruder and Dr. Aaron Frenette (University of Waterloo) for the recombinant antigens used in the serology assays, and Carmen Venegas for assistance with participant recruitment and data collection.

References

392

- 393 1. Alon R, Sportiello M, Kozlovski S, Kumar A, Reilly EC, Zarbock A, et al. Leukocyte trafficking to the
- lungs and beyond: lessons from influenza for COVID-19. Nature Reviews Immunology. 2021;21(1):49-64.
- 395 doi: 10.1038/s41577-020-00470-2.
- 396 2. Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic
- review and meta-analysis. Journal of Intensive Care. 2020;8(1):36. doi: 10.1186/s40560-020-00453-4.
- 398 3. Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nature Reviews Immunology.
- 399 2020;20(9):529-36. doi: 10.1038/s41577-020-0402-6.
- 400 4. de Candia P, Prattichizzo F, Garavelli S, Matarese G. T Cells: Warriors of SARS-CoV-2 Infection.
- 401 Trends Immunol. 2021;42(1):18-30. Epub 2020/12/06. doi: 10.1016/j.it.2020.11.002. PubMed PMID:
- 402 33277181; PubMed Central PMCID: PMCPMC7664351.
- 403 5. Zhang D, Guo R, Lei L, Liu H, Wang Y, Wang Y, et al. COVID-19 infection induces readily detectable
- morphologic and inflammation-related phenotypic changes in peripheral blood monocytes. Journal of
- 405 leukocyte biology. 2020.
- 406 6. Prescott HC, Girard TD. Recovery From Severe COVID-19: Leveraging the Lessons of Survival From
- 407 Sepsis. JAMA. 2020;324(8):739-40. doi: 10.1001/jama.2020.14103.
- 408 7. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in
- 409 primary care. BMJ. 2020;370:m3026. doi: 10.1136/bmj.m3026.
- 410 8. Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, et al. Post-covid
- 411 syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ.
- 412 2021;372:n693. doi: 10.1136/bmj.n693.
- 413 9. Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-Day Outcomes Among Patients
- 414 Hospitalized With COVID-19. Ann Intern Med. 2020. Epub 2020/11/12. doi: 10.7326/m20-5661. PubMed
- 415 PMID: 33175566; PubMed Central PMCID: PMCPMC7707210
- 416 www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-5661.
- 417 10. Donnelly JP, Wang XQ, Iwashyna TJ, Prescott HC. Readmission and Death After Initial Hospital
- 418 Discharge Among Patients With COVID-19 in a Large Multihospital System. JAMA. 2020. doi:
- 419 10.1001/jama.2020.21465.
- 420 11. Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond SI, et al. Epidemiology of
- 421 post-COVID syndrome following hospitalisation with coronavirus: a retrospective cohort study. medRxiv.
- 422 2021:2021.01.15.21249885. doi: 10.1101/2021.01.15.21249885.
- 423 12. Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin JB, Olsson A, et al. Robust T Cell
- Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020;183(1):158-68 e14.
- 425 Epub 2020/09/28. doi: 10.1016/j.cell.2020.08.017. PubMed PMID: 32979941; PubMed Central PMCID:
- 426 PMCPMC7427556.
- 427 13. Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin J-B, Olsson A, et al. Robust T Cell
- 428 Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020;183(1):158-68.e14.
- 429 doi: https://doi.org/10.1016/j.cell.2020.08.017.
- 430 14. Verschoor CP, Kohli V, Balion C. A comprehensive assessment of immunophenotyping performed in
- cryopreserved peripheral whole blood. Cytometry B Clin Cytom. 2018;94(5):662-70. Epub 2017/04/06. doi:
- 432 10.1002/cyto.b.21526. PubMed PMID: 28378896.
- Huynh A, Arnold DM, Smith JW, Moore JC, Zhang A, Chagla Z, et al. Characteristics of Anti-SARS-
- 434 CoV-2 Antibodies in Recovered COVID-19 Subjects. Viruses. 2021;13(4):697. PubMed PMID:
- 435 doi:10.3390/v13040697.

- 436 16. Zaunders JJ, Munier ML, Seddiki N, Pett S, Ip S, Bailey M, et al. High Levels of Human Antigen-
- 437 Specific CD4⁺ T Cells in Peripheral Blood Revealed by Stimulated Coexpression of CD25 and CD134 (OX40).
- 438 The Journal of Immunology. 2009;183(4):2827-36. doi: 10.4049/jimmunol.0803548.
- 439 17. Seddiki N, Cook L, Hsu DC, Phetsouphanh C, Brown K, Xu Y, et al. Human antigen-specific CD4(+)
- 440 CD25(+) CD134(+) CD39(+) T cells are enriched for regulatory T cells and comprise a substantial proportion
- of recall responses. Eur J Immunol. 2014;44(6):1644-61. Epub 2014/04/23. doi: 10.1002/eji.201344102.
- 442 PubMed PMID: 24752698.
- 443 18. Wolfl M, Kuball J, Ho WY, Nguyen H, Manley TJ, Bleakley M, et al. Activation-induced expression of
- 444 CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to
- antigen without requiring knowledge of epitope specificities. Blood. 2007;110(1):201-10. Epub 2007/03/21.
- doi: 10.1182/blood-2006-11-056168. PubMed PMID: 17371945; PubMed Central PMCID:
- 447 PMCPMC1896114.
- Loukov D, Karampatos S, Maly MR, Bowdish DME. Monocyte activation is elevated in women with
- knee-osteoarthritis and associated with inflammation, BMI and pain. Osteoarthritis Cartilage.
- 450 2018;26(2):255-63. Epub 2017/11/13. doi: 10.1016/j.joca.2017.10.018. PubMed PMID: 29128509.
- 451 20. Ontario). OAfHPaPPH. COVID-19 Serosurveillance Summary Seroprevalence in Ontario: March 27,
- 452 2020 to June 30, 2020. In: Ontario PH, editor. Toronto: Queen's Printer for Ontario; 2020.
- 453 21. Canada Go. Respiratory Virus Report, week 34 ending August 22, 2020 2020. Available from:
- 454 https://www.canada.ca/en/public-health/services/surveillance/respiratory-virus-detections-canada/2019-
- 455 <u>2020/week-34-ending-august-22-2020.html.</u>
- 456 22. Sadler R, Bateman EA, Heath V, Patel SY, Schwingshackl PP, Cullinane AC, et al. Establishment of a
- 457 healthy human range for the whole blood "OX40" assay for the detection of antigen-specific CD4+ T cells by
- 458 flow cytometry. Cytometry B Clin Cytom. 2014;86(5):350-61. Epub 2014/05/16. doi: 10.1002/cyto.b.21165.
- 459 PubMed PMID: 24827553.
- 460 23. Zaunders JJ, Munier ML, Seddiki N, Pett S, Ip S, Bailey M, et al. High levels of human antigen-
- specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J
- 462 Immunol. 2009;183(4):2827-36. Epub 2009/07/29. doi: 10.4049/jimmunol.0803548. PubMed PMID:
- 463 19635903.
- 464 24. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, et al. Selective and cross-reactive SARS-
- 465 CoV-2 T cell epitopes in unexposed humans. Science. 2020;370(6512):89-94.
- 466 25. Honigsbaum M, Krishnan L. Taking pandemic sequelae seriously: from the Russian influenza to
- 467 COVID-19 long-haulers. Lancet. 2020;396(10260):1389-91. Epub 2020/10/16. doi: 10.1016/s0140-
- 468 6736(20)32134-6. PubMed PMID: 33058777; PubMed Central PMCID: PMCPMC7550169.
- 469 26. Mahase E. Covid-19: What do we know about "long covid"? Bmj. 2020;370:m2815. Epub
- 470 2020/07/16. doi: 10.1136/bmj.m2815. PubMed PMID: 32665317.
- 471 27. Kratofil RM, Kubes P, Deniset JF. Monocyte Conversion During Inflammation and Injury.
- 472 Arteriosclerosis, Thrombosis, and Vascular Biology. 2017;37(1):35-42. doi:
- 473 doi:10.1161/ATVBAHA.116.308198.
- 474 28. El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, et al. Ccr2 deficiency impairs
- 475 microglial accumulation and accelerates progression of Alzheimer-like disease. Nature Medicine.
- 476 2007;13(4):432-8. doi: 10.1038/nm1555.
- 477 29. Auffray C, Fogg D, Garfa M, Elain G, Join-Lambert O, Kayal S, et al. Monitoring of blood vessels and
- tissues by a population of monocytes with patrolling behavior. Science. 2007;317(5838):666-70.
- 479 30. Thomas G, Tacke R, Hedrick CC, Hanna RN. Nonclassical Patrolling Monocyte Function in the
- 480 Vasculature. Arteriosclerosis, Thrombosis, and Vascular Biology. 2015;35(6):1306-16. doi:
- 481 doi:10.1161/ATVBAHA.114.304650.
- 482 31. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequalae of COVID-19.
- 483 Nature. 2021. doi: 10.1038/s41586-021-03553-9.

- 484 32. Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-
- Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease
- 486 Severity. Cell. 2020;183(4):996-1012.e19. Epub 2020/10/05. doi: 10.1016/j.cell.2020.09.038. PubMed
- 487 PMID: 33010815; PubMed Central PMCID: PMCPMC7494270.
- 488 33. Sanchez AM, Zhu J, Huang X, Yang Y. The Development and Function of Memory Regulatory T Cells
- after Acute Viral Infections. The Journal of Immunology. 2012;189(6):2805-14. doi:
- 490 10.4049/jimmunol.1200645.
- 491 34. Betts RJ, Prabhu N, Ho AWS, Lew FC, Hutchinson PE, Rotzschke O, et al. Influenza A Virus Infection
- 492 Results in a Robust, Antigen-Responsive, and Widely Disseminated Foxp3⁺ Regulatory T Cell Response.
- 493 Journal of Virology. 2012;86(5):2817-25. doi: 10.1128/jvi.05685-11.
- 494 35. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against
- type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515). Epub 2020/09/26. doi:
- 496 10.1126/science.abd4585. PubMed PMID: 32972996; PubMed Central PMCID: PMCPMC7857397.
- 497 36. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe
- Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study.
- 499 Lancet. 2020;395(10239):1771-8. Epub 2020/05/16. doi: 10.1016/s0140-6736(20)31103-x. PubMed PMID:
- 32410760; PubMed Central PMCID: PMCPMC7220177.
- 37. Ramos-Casals M, Brito-Zerón P, Mariette X. Systemic and organ-specific immune-related
- manifestations of COVID-19. Nature Reviews Rheumatology. 2021. doi: 10.1038/s41584-021-00608-z.
- 503 38. Lanteri MC, O'Brien KM, Purtha WE, Cameron MJ, Lund JM, Owen RE, et al. Tregs control the
- development of symptomatic West Nile virus infection in humans and mice. The Journal of Clinical
- 505 Investigation. 2009;119(11):3266-77. doi: 10.1172/JCl39387.
- 506 39. Stukalov A, Girault V, Grass V, Karayel O, Bergant V, Urban C, et al. Multilevel proteomics reveals
- 507 host perturbations by SARS-CoV-2 and SARS-CoV. Nature. 2021. Epub 2021/04/13. doi: 10.1038/s41586-
- 508 021-03493-4. PubMed PMID: 33845483.
- 509 40. Sun X, Cui Y, Feng H, Liu H, Liu X. TGF-β signaling controls Foxp3 methylation and T reg cell
- 510 differentiation by modulating Uhrf1 activity. Journal of Experimental Medicine. 2019;216(12):2819-37. doi:
- 511 10.1084/jem.20190550.
- Lüke F, Orsó E, Kirsten J, Poeck H, Grube M, Wolff D, et al. Coronavirus disease 2019 induces multi-
- 513 lineage, morphologic changes in peripheral blood cells. EJHaem. 2020. Epub 2020/08/25. doi:
- 514 10.1002/jha2.44. PubMed PMID: 32838398; PubMed Central PMCID: PMCPMC7361732.
- 515 42. Schulte-Schrepping J, Reusch N, Paclik D, Baßler K, Schlickeiser S, Zhang B, et al. Severe COVID-19 Is
- Marked by a Dysregulated Myeloid Cell Compartment. Cell. 2020;182(6):1419-40.e23. Epub 2020/08/19.
- doi: 10.1016/j.cell.2020.08.001. PubMed PMID: 32810438; PubMed Central PMCID: PMCPMC7405822.
- 518 43. Pérez-Gómez A, Vitallé J, Gasca-Capote C, Gutierrez-Valencia A, Trujillo-Rodriguez M, Serna-Gallego
- A, et al. Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection. Cellular & Molecular
- 520 Immunology. 2021. doi: 10.1038/s41423-021-00728-2.
- 521 44. McKechnie JL, Blish CA. The Innate Immune System: Fighting on the Front Lines or Fanning the
- 522 Flames of COVID-19? Cell Host Microbe. 2020;27(6):863-9. Epub 2020/05/29. doi:
- 523 10.1016/j.chom.2020.05.009. PubMed PMID: 32464098; PubMed Central PMCID: PMCPMC7237895.
- 524 45. Miller LJ, Bainton DF, Borregaard N, Springer TA. Stimulated mobilization of monocyte Mac-1 and
- 525 p150,95 adhesion proteins from an intracellular vesicular compartment to the cell surface. The Journal of
- 526 clinical investigation. 1987;80(2):535-44. doi: 10.1172/JCl113102. PubMed PMID: 3038962.

Supporting information

527

Supplementary Figure 1. Gating strategies for flow cytometry data analysis

Supplementary Table 1. Criteria and identification of individuals with SARS-CoV-2 and other respiratory

infections

Supplementary Table 2. Fluorophore-conjugated antibodies used for flow cytometry

Supplementary Table 3. Summary of SARS-CoV-2 peptivator AIMS T cell activation observations

Supplementary Table 4. All immune parameter data analysis

Supplementary Table 5. Monocyte surface receptor expression as Mean Fluorescence Intensity (MFI)

Figure 1




Figure 2






Figure 3





EMRA (CD45RA+ CCR7-)

TD (CD45RA+ CCR7- CD57+ CD28-)




Figure 5

